Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial
Author:
Affiliation:
1. Department of Ophthalmology, University of Pennsylvania, Philadelphia
2. Department of Ophthalmology, Duke University, Durham, North Carolina
3. Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
Publisher
American Medical Association (AMA)
Subject
Ophthalmology
Link
https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2762852/jamaophthalmology_daniel_2020_oi_200015.pdf
Reference35 articles.
1. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.;CATT Research Group;N Engl J Med,2011
2. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.;Martin;Ophthalmology,2012
3. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.;Maguire;Ophthalmology,2016
4. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.;Gemenetzi;Eye (Lond),2017
5. Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials.;Grunwald;Ophthalmology,2017
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gene and cell therapy for age-related macular degeneration: A review;Survey of Ophthalmology;2024-09
2. Botulinum toxin type A in multimodal management of age-related macular degeneration and related diseases;Toxicon;2023-12
3. Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration;Translational Vision Science & Technology;2023-09-01
4. iPSC-RPE in Retinal Degeneration: Recent Advancements and Future Perspectives;Cold Spring Harbor Perspectives in Medicine;2023-01-23
5. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age‐related macular degeneration;Acta Ophthalmologica;2022-11-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3